AptarGroup Inc.

ATR | NYSE

Price Alert Chart Builder DCF Calculator

$137.20

+$6.56 (+5.02%)

At close: Oct 30, 2026, 4:00 PM ET

$139.99

+$2.79 (+2.03%)

Pre-market: Nov 2, 2026, 7:03 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

+5.02%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

38.6

-7.8 pts

Fundamentals Average

Market Sentiment Neutral

Moat Narrow

Sector Rank #563/1028 (Top 55%)

Full Analysis

Key Statistics

Market Data

Market Cap $8.72B

1D Range

135.69 142.31

52W Range

111.94 145.72

Valuation (TTM)

PE 33.30

PB 3.34

EV/EBITDA 13.52

Valuation (NTM)

Forward PE 21.33

Forward PEG -8.69

Price Target $148.33

Cash Flow

FCF Yield 3.4%

SBC Adj. FCF Yield 3.0%

SBC Impact -11.1%

Margins

Gross Margin 28.1%

Operating Margin 12.1%

FCF Margin 7.4%

Growth (CAGR)

Revenue 3Y | 5Y 5.0% | 4.8%

Dil EPS 3Y | 5Y -0.7% | 3.1%

FCF 3Y | 5Y 12.2% | 13.5%

Returns

ROA 5.2%

ROE 10.1%

ROIC 8.4%

Financial Health

Net Debt

$1.16B

Current Ratio 1.50

Interest Coverage 7.34

Dividends

Div Yield 1.40%

Payout Ratio 46.6%

FCF Payout Ratio 41.9%

All Key Statistics

Loading financial charts...

Profile

AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care,...

Sector Healthcare

Industry Medical - Instruments & Supplies

Employees 14,000

IPO Date Apr 23, 1993

Website www.aptar.com

Fiscal Year January - December

Full Company Profile

Latest News

6 hours ago · prnewswire.com

Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026

-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRKAG2 syndrome -- -- Poster presentation November 6 at 5:30 p.m. CT -- SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome during Hypertrophic Cardiomyopathy Medical Society at the American Heart Association Scientific Sessions 2026, taking place on November 6, 2026, in Chicago, Illinois.

7 hours ago · fool.com

Aptar: 3 Key Takeaways for Long-Term Investors

Beauty sales surged 8% but margins stumbled in North America, exposing an execution gap management must close.

2 days ago · seekingalpha.com

AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript

AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO, President & Director Vanessa Kanu - Executive VP & CFO Conference Call Participants Ghansham Panjabi - Robert W. Baird & Co. Incorporated, Research Division Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Roberts - Raymond James & Associates, Inc., Research Division George Staphos - BofA Securities, Research Division Matthew Larew - William Blair & Company L.L.C.

3 days ago · marketbeat.com

What AptarGroup (ATR) Said on Its Q3 Earnings Call

AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and Closures weighed on results.

3 days ago · zacks.com

AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates

AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.

5 days ago · globenewswire.com

Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program

EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research

28 days ago · zacks.com

AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

1 month ago · zacks.com

3 Packaging Stocks Worth Watching Despite Industry Pressure

Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.